scispace - formally typeset
Open AccessJournal ArticleDOI

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

TLDR
SD-36 achieves complete and long-lasting tumor regression in multiple xenograft mouse models at well-tolerated dose schedules and is a promising cancer therapeutic strategy.
About
This article is published in Cancer Cell.The article was published on 2019-11-11 and is currently open access. It has received 311 citations till now. The article focuses on the topics: STAT3 & Myeloid leukemia.

read more

Citations
More filters
Journal ArticleDOI

PROTACs: great opportunities for academia and industry.

TL;DR: Although PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.
Journal ArticleDOI

Targeting STAT3 in Cancer Immunotherapy

TL;DR: The importance of STAT3 signaling pathway in tumorigenesis and its immune regulation is outlined, the current status for the development ofSTAT3-targeting therapeutic approaches is highlighted, and recent advances in STAT3-based combination immunotherapy are discussed.
Journal ArticleDOI

PROTACs: An Emerging Therapeutic Modality in Precision Medicine.

TL;DR: This review highlights the key advantages of PROTACs and then discusses the spatiotemporal regulation of protein degradation, and explores current chemically tractable E3 ligases focusing on expanding the existing repertoire with novel E3ligases to uncover the full potential of TPD.
Journal ArticleDOI

Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy.

TL;DR: In this paper, a semiconducting polymer nano-PROTAC (SPNpro) with phototherapeutic and activatable protein degradation abilities for photo-immunometabolic cancer therapy is presented.
Journal ArticleDOI

Advancing targeted protein degradation for cancer therapy.

TL;DR: In this paper, the molecular basis of targeted protein degradation is discussed and a comprehensive review of the most promising degraders in development as cancer therapies to date is provided, with a focus on opportunities and challenges for future development.
References
More filters
Book ChapterDOI

Processing of X-ray diffraction data collected in oscillation mode

TL;DR: The methods presented in the chapter have been applied to solve a large variety of problems, from inorganic molecules with 5 A unit cell to rotavirus of 700 A diameters crystallized in 700 × 1000 × 1400 A cell.
Journal ArticleDOI

Features and development of Coot.

TL;DR: Coot is a molecular-graphics program designed to assist in the building of protein and other macromolecular models and the current state of development and available features are presented.
Journal ArticleDOI

Phaser crystallographic software

TL;DR: A description is given of Phaser-2.1: software for phasing macromolecular crystal structures by molecular replacement and single-wavelength anomalous dispersion phasing.
Journal ArticleDOI

MolProbity: all-atom structure validation for macromolecular crystallography

TL;DR: MolProbity structure validation will diagnose most local errors in macromolecular crystal structures and help to guide their correction.
Related Papers (5)